Abstract library

1466 results for "lung tumors".
#2082 Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors
Introduction: Lung neuroendocrine tumors are rare, but their incidence has been steadily increasing in recent years.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anna Kuznetsova
#2020 Expression of Somatostatin Receptors in Neuroendocrine Tumors of the Lungs with Various Degrees of Malignancy
Introduction: Diagnostics and management of patients with neuroendocrine tumors of the lung requires an individual approach
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Larisa Gurevich
#1689 The Prognostic Value of the Expression of Cytokeratin 7 and 19 in Lungs and Pancreas Neuroendocrine Tumors
Introduction: The expression of cytokeratins (CK) 7,19 rarely occurs in the low grade neuroendocrine tumors (NET) of lung and pancreas. It is known that part of the low grade typical (TC) and atypical (ATС) carcinoids of lung and pancreas (pNET-G1,G2) can progress quickly and to metastasize. It is important to distinguish NET with a less differentiated cells immunophentype.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Iya A Voronkova
#1606 Tumor Growth Rate to Assess Tumor Activity in Patients with Lung Neuroendocrine Tumors on Lanreotide Autogel: A Case-Series Analysis
Introduction: The slow-growing character of neuroendocrine tumors (NET) makes it difficult to assess treatment impact on tumor growth.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Frank van Fraeyenhove
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
#580 Diagnostic Performance of Dual Tracer PET/CT in Staging Neuroendocrine Tumors of the Lung
Introduction: Different positron emission tomography/computed tomography (PET/CT) tracers may be useful in staging lung neuroendocrine tumors (LNETs)
Conference:
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
#78 The diagnostic and prognostic value of elevated proGRP levels in well- and moderately differentiated neuroendocrine tumors
Introduction: Chromogranin A (CgA) is the most frequently used marker in well- (grade 1) and moderately (grade 2) differentiated NETs. Although CgA is a more sensitive marker than the 5-HIAA, which was widely used until the last decade, CgA has some limitations. False-positively elevated CgA may occur in renal impairment, atrophic gastritis and during treatment of proton-pump inhibitors. Progastrin-releasing peptide (proGRP) was recently reported as a promising tumor marker for small cell lung cancer. Limited data suggests that ProGRP may be a potential tumor marker in NE tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Msc Catharina M Korse
#1082 Characterization and Prognosis of Patients with Metastatic Lung Carcinoid Tumors
Introduction: Data on metastatic lung carcinoid tumors are limited.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD, PhD Thomas Walter
#1672 PD-L1 Expression and Quantitative Assessment of Tumor-Infiltrating T Cell Subsets in Carcinoid Tumors and Large Cell Neuroendocrine Carcinomas of the Lung
Introduction: Little is known about the expression of PD-L1 an the immune infiltrate in neuroendocrine neoplasms of the lung.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Julien Hadoux
#2017 Data on Healthcare Resource Utilization (HCRU) and Treatment Modalities in Patients (Pts) with Advanced (adv), Well-Differentiated (WD) Neuroendocrine Tumors (NETs) of Gastrointestinal (GI) or Lung Origin in Finland
Introduction: The majority of all NETs develop in the GI tract and about one third develop in the lungs; approximately 43% and 51% of pts, respectively, are diagnosed with adv disease (regional or distant metastasis). While GI and lung NETs are rare, their incidence has increased markedly over the past four decades. The severe and progressive nature of adv NET suggests significant costs for pts and payers.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Lotte Gaasvik
Keywords: NET, HCRU, GI, Lung
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.